In prostatic cancer cells with downregulated AR expression by short interfering RNA, treatment with sorafenib increased apoptosis in an additive manner [43], suggesting that there might be a potential to use inhibitors of AR in HCC as an adjuvant therapy option for sorafenib-resistant HCC patients. This evidence concerns the gene AR and Familial prostate cancer.